Cepeda Mario A, Pelling Jacob J H, Evered Caitlin L, Williams Karla C, Freedman Zoey, Stan Ioana, Willson Jessica A, Leong Hon S, Damjanovski Sashko
Department of Biology, Faculty of Science, University of Western Ontario, 1151 Richmond St N., London, Ontario, N6A 5B7, Canada.
Translational Prostate Cancer Research Laboratory, Lawson Health Research Institute, London, ON, Canada.
Mol Cancer. 2016 Oct 18;15(1):65. doi: 10.1186/s12943-016-0547-x.
Membrane Type-1 Matrix Metalloproteinase (MT1-MMP) is a multifunctional protease implicated in metastatic progression ostensibly due to its ability to degrade extracellular matrix (ECM) components and allow migration of cells through the basement membrane. Despite in vitro studies demonstrating this principle, this knowledge has not translated into the use of MMP inhibitors (MMPi) as effective cancer therapeutics, or been corroborated by evidence of in vivo ECM degradation mediated by MT1-MMP, suggesting that our understanding of the role of MT1-MMP in cancer progression is incomplete.
MCF-7 and MDA-MB 231 breast cancer cell lines were created that stably overexpress different levels of MT1-MMP. Using 2D culture, we analyzed proMMP-2 activation (gelatin zymography), ECM degradation (fluorescent gelatin), ERK signaling (immunoblot), cell migration (transwell/scratch closure/time-lapse imaging), and viability (colorimetric substrate) to assess how different MT1-MMP levels affect these cellular parameters. We also utilized Matrigel 3D cell culture and avian embryos to examine how different levels of MT1-MMP expression affect morphological changes in 3D culture, and tumourigenecity and extravasation efficiency in vivo.
In 2D culture, breast cancer cells expressing high levels of MT1-MMP were capable of widespread ECM degradation and TIMP-2-mediated proMMP-2 activation, but were not the most migratory. Instead, cells expressing low levels of MT1-MMP were the most migratory, and demonstrated increased viability and ERK activation. In 3D culture, MCF-7 breast cancer cells expressing low levels of MT1-MMP demonstrated an invasive protrusive phenotype, whereas cells expressing high levels of MT1-MMP demonstrated loss of colony structure and cell fragment release. Similarly, in vivo analysis demonstrated increased tumourigenecity and metastatic capability for cells expressing low levels of MT1-MMP, whereas cells expressing high levels were devoid of these qualities despite the production of functional MT1-MMP protein.
This study demonstrates that excessive ECM degradation mediated by high levels of MT1-MMP is not associated with cell migration and tumourigenesis, while low levels of MT1-MMP promote invasion and vascularization in vivo.
膜型-1基质金属蛋白酶(MT1-MMP)是一种多功能蛋白酶,表面上因其能够降解细胞外基质(ECM)成分并使细胞通过基底膜迁移而与转移进展相关。尽管体外研究证明了这一原理,但这一知识尚未转化为将基质金属蛋白酶抑制剂(MMPi)用作有效的癌症治疗方法,也未得到MT1-MMP介导的体内ECM降解证据的证实,这表明我们对MT1-MMP在癌症进展中的作用的理解并不完整。
构建了稳定过表达不同水平MT1-MMP的MCF-7和MDA-MB 231乳腺癌细胞系。使用二维培养,我们分析了前MMP-2激活(明胶酶谱法)、ECM降解(荧光明胶)、ERK信号传导(免疫印迹)、细胞迁移(Transwell/划痕闭合/延时成像)和活力(比色底物),以评估不同水平的MT1-MMP如何影响这些细胞参数。我们还利用基质胶三维细胞培养和鸡胚来研究不同水平的MT1-MMP表达如何影响三维培养中的形态变化以及体内的肿瘤发生和外渗效率。
在二维培养中,表达高水平MT1-MMP的乳腺癌细胞能够广泛降解ECM并通过TIMP-2介导激活前MMP-2,但不是迁移能力最强的。相反,表达低水平MT1-MMP的细胞迁移能力最强,并表现出活力增加和ERK激活。在三维培养中,表达低水平MT1-MMP的MCF-7乳腺癌细胞表现出侵袭性突出表型,而表达高水平MT1-MMP的细胞则表现出集落结构丧失和细胞碎片释放。同样,体内分析表明,表达低水平MT1-MMP的细胞肿瘤发生和转移能力增加,而表达高水平MT1-MMP的细胞尽管产生了功能性MT1-MMP蛋白,但缺乏这些特性。
本研究表明,高水平MT1-MMP介导的过度ECM降解与细胞迁移和肿瘤发生无关,而低水平的MT1-MMP促进体内侵袭和血管生成。